百诚医药
(301096)
| 流通市值：24.63亿 | | | 总市值：38.74亿 |
| 流通股本：6943.03万 | | | 总股本：1.09亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 242,990,244.62 | 615,453,537.69 | 790,555,445.57 | 881,929,187.54 |
| 应收票据及应收账款 | 396,769,547.15 | 357,939,297.23 | 252,875,164.08 | 213,203,221.46 |
| 其中：应收票据 | 6,953,658.37 | 3,962,578.5 | 4,457,917 | 13,283,651.38 |
| 应收账款 | 389,815,888.78 | 353,976,718.73 | 248,417,247.08 | 199,919,570.08 |
| 预付款项 | 66,917,635.61 | 42,948,810.94 | 53,517,735.32 | 42,284,124.98 |
| 其他应收款合计 | 3,166,591.28 | 3,355,563.75 | 3,160,017.64 | 4,097,997.87 |
| 存货 | 149,222,182.01 | 152,317,234.62 | 123,746,092.38 | 93,173,602.59 |
| 合同资产 | 437,813,625.17 | 416,383,215.68 | 369,736,213.16 | 318,976,691.13 |
| 其他流动资产 | 75,192,042.95 | 62,787,668.02 | 75,981,291.87 | 54,119,099.46 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,591,071,868.79 | 1,734,845,327.93 | 1,669,571,960.02 | 1,607,783,925.03 |
| 非流动资产: | | | | |
| 长期股权投资 | 17,569,709.37 | 16,434,086.48 | 16,523,250.61 | 16,362,054.68 |
| 其他非流动金融资产 | 132,352,267.6 | 132,352,267.6 | 125,506,267.6 | 120,506,267.6 |
| 固定资产 | 1,602,659,648.9 | 1,631,351,042.66 | 1,656,551,353.14 | 1,290,616,675.28 |
| 在建工程 | 191,329,105.54 | 172,690,064.76 | 164,316,956.51 | 448,816,461.27 |
| 使用权资产 | 3,476,884.05 | 990,845.65 | 1,050,264.41 | 1,137,902.66 |
| 无形资产 | 91,879,377.35 | 104,830,567.06 | 92,783,509.89 | 92,070,166.52 |
| 长期待摊费用 | 53,258.94 | 359,662.53 | 176,553.85 | 246,589.96 |
| 递延所得税资产 | 63,803,027.79 | 61,640,131.69 | 52,430,560.22 | 48,426,196.55 |
| 其他非流动资产 | 65,708,534.65 | 57,132,568.77 | 55,780,268.6 | 43,139,897.56 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,168,831,814.19 | 2,177,781,237.2 | 2,165,118,984.83 | 2,061,322,212.08 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 3,759,903,682.98 | 3,912,626,565.13 | 3,834,690,944.85 | 3,669,106,137.11 |
| 流动负债: | | | | |
| 短期借款 | 558,819,577.78 | 633,876,063.89 | 634,023,813.91 | 369,319,550.02 |
| 应付票据及应付账款 | 132,207,373.76 | 173,379,471.92 | 233,871,157.79 | 323,381,376.21 |
| 其中：应付票据 | 17,610,319.29 | 49,809,932.55 | 100,355,197.05 | 103,418,472.6 |
| 应付账款 | 114,597,054.47 | 123,569,539.37 | 133,515,960.74 | 219,962,903.61 |
| 合同负债 | 92,728,456.94 | 90,796,615.51 | 64,014,704.69 | 74,012,974.58 |
| 应付职工薪酬 | 22,948,324.49 | 22,882,193.67 | 22,041,317.01 | 64,507,072.83 |
| 应交税费 | 9,245,049.83 | 12,603,115.16 | 7,855,318.7 | 12,087,325.1 |
| 其他应付款合计 | 5,244,974.86 | 7,930,504.38 | 1,216,701.86 | 2,497,721.29 |
| 一年内到期的非流动负债 | 706,866.19 | 392,254.03 | 395,110.7 | 384,687.92 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 821,900,623.85 | 941,860,218.56 | 963,418,124.66 | 846,190,707.95 |
| 非流动负债: | | | | |
| 长期借款 | 40,030,000 | 40,022,500 | - | - |
| 租赁负债 | 3,049,950.59 | 848,805.68 | 913,491.58 | 933,051.39 |
| 预计负债 | 91,393,309.88 | 92,187,347.7 | 89,466,375.86 | 97,170,480.29 |
| 递延收益 | 33,426,044.9 | 37,014,137.84 | 39,504,430.08 | 40,674,766.36 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 167,899,305.37 | 170,072,791.22 | 129,884,297.52 | 138,778,298.04 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 989,799,929.22 | 1,111,933,009.78 | 1,093,302,422.18 | 984,969,005.99 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 109,228,284 | 108,919,903 | 108,919,903 | 108,919,903 |
| 资本公积 | 2,102,747,583.59 | 2,141,014,635.99 | 2,134,110,960.5 | 2,126,676,428.24 |
| 减:库存股 | 49,998,224.77 | 49,998,224.77 | 49,998,224.77 | 49,998,224.77 |
| 其他综合收益 | -133,938.4 | -136,694.88 | -137,536.8 | -136,186.95 |
| 盈余公积 | 54,459,951.5 | 54,459,951.5 | 54,459,951.5 | 54,459,951.5 |
| 未分配利润 | 553,428,612.54 | 545,982,993.38 | 494,033,469.24 | 444,215,260.1 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,769,732,268.46 | 2,800,242,564.22 | 2,741,388,522.67 | 2,684,137,131.12 |
| 少数股东权益 | 371,485.3 | 450,991.13 | - | - |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,770,103,753.76 | 2,800,693,555.35 | 2,741,388,522.67 | 2,684,137,131.12 |
| 负债和股东权益合计 | 3,759,903,682.98 | 3,912,626,565.13 | 3,834,690,944.85 | 3,669,106,137.11 |
| 公告日期 | 2024-10-29 | 2024-08-15 | 2024-04-23 | 2024-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |